Kyprolis Approval History
- FDA approved: Yes (First approved July 20th, 2012)
- Brand name: Kyprolis
- Generic name: carfilzomib
- Dosage form: Injection
- Company: Amgen Inc.
- Treatment for: Multiple Myeloma
Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma.
Development History and FDA Approval Process for Kyprolis
|Jan 21, 2016|| FDA Approves New Kyprolis (Carfilzomib) Combination Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma|
|Jul 24, 2015|| FDA Approves Kyprolis (carfilzomib) for Combination Treatment of Patients with Relapsed Multiple Myeloma|
|Jul 20, 2012|| FDA Approves Kyprolis for Patients with Advanced Multiple Myeloma|
|Jun 21, 2012||Onyx Pharmaceuticals' Kyprolis Receives Positive Vote from Oncologic Drugs Advisory Committee (ODAC)|
|Jun 19, 2012||Onyx Pharmaceuticals to Hold Conference Call on June 20, 2012 to Discuss FDA Advisory Committee Recommendation for Kyprolis|
|Apr 27, 2012||Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma|
|Nov 29, 2011||Onyx Pharmaceuticals Announces FDA Acceptance of New Drug Application for Carfilzomib for the Treatment of Relapsed and Refractory Multiple Myeloma|
|Oct 12, 2011||Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma|
|Oct 8, 2010||Onyx Pharmaceuticals Provides Status Update on Carfilzomib|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.